Cargando…

An LC-MS/MS method for simultaneous analysis of the cystic fibrosis therapeutic drugs colistin, ivacaftor and ciprofloxacin

Inhaled antibiotics such as colistin and ciprofloxacin are increasingly used to treat bacterial lung infections in cystic fibrosis patients. In this study, we established and validated a new HPLC-MS/MS method that could simultaneously detect drug concentrations of ciprofloxacin, colistin and ivacaft...

Descripción completa

Detalles Bibliográficos
Autores principales: Yuan, Huiya, Yu, Shihui, Chai, Guihong, Liu, Junting, Zhou, Qi (Tony)
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Xi'an Jiaotong University 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8740159/
https://www.ncbi.nlm.nih.gov/pubmed/35028178
http://dx.doi.org/10.1016/j.jpha.2021.02.004
_version_ 1784629253812256768
author Yuan, Huiya
Yu, Shihui
Chai, Guihong
Liu, Junting
Zhou, Qi (Tony)
author_facet Yuan, Huiya
Yu, Shihui
Chai, Guihong
Liu, Junting
Zhou, Qi (Tony)
author_sort Yuan, Huiya
collection PubMed
description Inhaled antibiotics such as colistin and ciprofloxacin are increasingly used to treat bacterial lung infections in cystic fibrosis patients. In this study, we established and validated a new HPLC-MS/MS method that could simultaneously detect drug concentrations of ciprofloxacin, colistin and ivacaftor in rat plasma, human epithelial cell lysate, cell culture medium, and drug transport media. An aliquot of 200 μL drug-containing rat plasma or cell culture medium was treated with 600 μL of extraction solution (acetonitrile containing 0.1% formic acid and 0.2% trifluoroacetic acid (TFA)). The addition of 0.2% TFA helped to break the drug-protein bonds. Moreover, the addition of 0.1% formic acid to the transport medium and cell lysate samples could significantly improve the response and reproducibility. After vortexing and centrifuging, the sample components were analyzed by HPLC-MS/MS. The multiple reaction monitoring mode was used to detect the following transitions: 585.5–101.1 (colistin A), 578.5–101.1 (colistin B), 393.2–337.2 (ivacaftor), 332.2–314.2 (ciprofloxacin), 602.3–101.1 (polymyxin B1 as internal standard (IS)) and 595.4–101.1 (polymyxin B2 as IS). The running time of a single sample was only 6 min, making this a time-efficient method. Linear correlations were found for colistin A at 0.029–5.82 μg/mL, colistin B at 0.016–3.14 μg/mL, ivacaftor at 0.05–10.0 μg/mL, and ciprofloxacin at 0.043–8.58 μg/mL. Accuracy, precision, and stability of the method were within the acceptable range. This method would be highly useful for research on cytotoxicity, animal pharmacokinetics, and in vitro drug delivery.
format Online
Article
Text
id pubmed-8740159
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Xi'an Jiaotong University
record_format MEDLINE/PubMed
spelling pubmed-87401592022-01-12 An LC-MS/MS method for simultaneous analysis of the cystic fibrosis therapeutic drugs colistin, ivacaftor and ciprofloxacin Yuan, Huiya Yu, Shihui Chai, Guihong Liu, Junting Zhou, Qi (Tony) J Pharm Anal Original Article Inhaled antibiotics such as colistin and ciprofloxacin are increasingly used to treat bacterial lung infections in cystic fibrosis patients. In this study, we established and validated a new HPLC-MS/MS method that could simultaneously detect drug concentrations of ciprofloxacin, colistin and ivacaftor in rat plasma, human epithelial cell lysate, cell culture medium, and drug transport media. An aliquot of 200 μL drug-containing rat plasma or cell culture medium was treated with 600 μL of extraction solution (acetonitrile containing 0.1% formic acid and 0.2% trifluoroacetic acid (TFA)). The addition of 0.2% TFA helped to break the drug-protein bonds. Moreover, the addition of 0.1% formic acid to the transport medium and cell lysate samples could significantly improve the response and reproducibility. After vortexing and centrifuging, the sample components were analyzed by HPLC-MS/MS. The multiple reaction monitoring mode was used to detect the following transitions: 585.5–101.1 (colistin A), 578.5–101.1 (colistin B), 393.2–337.2 (ivacaftor), 332.2–314.2 (ciprofloxacin), 602.3–101.1 (polymyxin B1 as internal standard (IS)) and 595.4–101.1 (polymyxin B2 as IS). The running time of a single sample was only 6 min, making this a time-efficient method. Linear correlations were found for colistin A at 0.029–5.82 μg/mL, colistin B at 0.016–3.14 μg/mL, ivacaftor at 0.05–10.0 μg/mL, and ciprofloxacin at 0.043–8.58 μg/mL. Accuracy, precision, and stability of the method were within the acceptable range. This method would be highly useful for research on cytotoxicity, animal pharmacokinetics, and in vitro drug delivery. Xi'an Jiaotong University 2021-12 2021-02-28 /pmc/articles/PMC8740159/ /pubmed/35028178 http://dx.doi.org/10.1016/j.jpha.2021.02.004 Text en © 2021 Xi'an Jiaotong University. Production and hosting by Elsevier B.V. https://creativecommons.org/licenses/by/4.0/This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Original Article
Yuan, Huiya
Yu, Shihui
Chai, Guihong
Liu, Junting
Zhou, Qi (Tony)
An LC-MS/MS method for simultaneous analysis of the cystic fibrosis therapeutic drugs colistin, ivacaftor and ciprofloxacin
title An LC-MS/MS method for simultaneous analysis of the cystic fibrosis therapeutic drugs colistin, ivacaftor and ciprofloxacin
title_full An LC-MS/MS method for simultaneous analysis of the cystic fibrosis therapeutic drugs colistin, ivacaftor and ciprofloxacin
title_fullStr An LC-MS/MS method for simultaneous analysis of the cystic fibrosis therapeutic drugs colistin, ivacaftor and ciprofloxacin
title_full_unstemmed An LC-MS/MS method for simultaneous analysis of the cystic fibrosis therapeutic drugs colistin, ivacaftor and ciprofloxacin
title_short An LC-MS/MS method for simultaneous analysis of the cystic fibrosis therapeutic drugs colistin, ivacaftor and ciprofloxacin
title_sort lc-ms/ms method for simultaneous analysis of the cystic fibrosis therapeutic drugs colistin, ivacaftor and ciprofloxacin
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8740159/
https://www.ncbi.nlm.nih.gov/pubmed/35028178
http://dx.doi.org/10.1016/j.jpha.2021.02.004
work_keys_str_mv AT yuanhuiya anlcmsmsmethodforsimultaneousanalysisofthecysticfibrosistherapeuticdrugscolistinivacaftorandciprofloxacin
AT yushihui anlcmsmsmethodforsimultaneousanalysisofthecysticfibrosistherapeuticdrugscolistinivacaftorandciprofloxacin
AT chaiguihong anlcmsmsmethodforsimultaneousanalysisofthecysticfibrosistherapeuticdrugscolistinivacaftorandciprofloxacin
AT liujunting anlcmsmsmethodforsimultaneousanalysisofthecysticfibrosistherapeuticdrugscolistinivacaftorandciprofloxacin
AT zhouqitony anlcmsmsmethodforsimultaneousanalysisofthecysticfibrosistherapeuticdrugscolistinivacaftorandciprofloxacin
AT yuanhuiya lcmsmsmethodforsimultaneousanalysisofthecysticfibrosistherapeuticdrugscolistinivacaftorandciprofloxacin
AT yushihui lcmsmsmethodforsimultaneousanalysisofthecysticfibrosistherapeuticdrugscolistinivacaftorandciprofloxacin
AT chaiguihong lcmsmsmethodforsimultaneousanalysisofthecysticfibrosistherapeuticdrugscolistinivacaftorandciprofloxacin
AT liujunting lcmsmsmethodforsimultaneousanalysisofthecysticfibrosistherapeuticdrugscolistinivacaftorandciprofloxacin
AT zhouqitony lcmsmsmethodforsimultaneousanalysisofthecysticfibrosistherapeuticdrugscolistinivacaftorandciprofloxacin